Brief: Mateon Announces Initiation Of Phase 1B Clinical Trial On Ot-101/Il-2 Combination Therapy For Solid Tumors
15/03/2021 11:35
March 15 (Reuters) - Mateon Therapeutics Inc MATN.PK :
* MATEON ANNOUNCES INITIATION OF PHASE 1B CLINICAL TRIAL ON
OT-101/IL-2 COMBINATION THERAPY FOR SOLID TUMORS
* MATEON THERAPEUTICS INC - STUDY WILL BE CONDUCTED TOGETHER
WITH
AUTOTELIC BIO- A PARTNER OF MATEON ON OT-101/IL-2 COMBINATION
Source text for Eikon: ID:nGNX7M8Yrk
Further company coverage: MATN.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas